Research programme: TIE-2 receptor agonists - Aerpio Pharmaceuticals

Drug Profile

Research programme: TIE-2 receptor agonists - Aerpio Pharmaceuticals

Alternative Names: AKB 9785

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Aerpio Therapeutics
  • Developer Aerpio Pharmaceuticals
  • Class Antibacterials; Small molecules
  • Mechanism of Action TIE-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 15 Mar 2017 Zeta Acquisition Corp II in a reverse merger transaction acquires Aerpio Therapeutics and changes its name to Aerpio Pharmaceuticals
  • 13 May 2016 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 13 May 2016 Pharmacodynamics data from a preclinical study in bacterial infections presented at the 112th International Conference of the American Thoracic Society (ATC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top